Addex Therapeutics Unveils Q3 2025 Financial Insights
Ad Hoc Announcement Pursuant to Art. 53 LR
In an exciting development, Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical firm specializing in novel allosteric modulators for neurological conditions, has shared its financial results for the third quarter and the first nine months of 2025, alongside a comprehensive corporate update.
Tim Dyer, the CEO of Addex Therapeutics, expressed enthusiasm about their progress. He stated, "We continue to make significant advancements with our GABAB positive allosteric modulator (PAM) candidate for chronic cough, showcasing strong anti-tussive effects in various preclinical models. We're also making strides with dipraglurant for post-stroke recovery."
Overview of Operational Highlights
Throughout the latest quarter, Addex Therapeutics has underscored its commitment to innovation:
- Advancement of their GABAB PAM chronic cough candidate through vital preclinical phases.
- Preparation of dipraglurant for entry into clinical studies focused on enhancing recovery following strokes.
Key Financial Metrics for Q3 2025
During the third quarter of 2025, Addex reported various financial metrics that shed light on the company's operational efficiency:
Financial Data Summary:
The following financial data highlights key changes from previous periods:
- Income: CHF 50,000 in Q3 2025, down from CHF 58,000 in Q3 2024.
- R&D Expenses: Increased to CHF (228,000) in Q3 2025, compared to CHF (204,000) a year prior.
- G&A Expenses: Slightly rose to CHF (518,000) from CHF (476,000) year-over-year.
- Total Operating Loss: A loss of CHF (696,000) in Q3 2025, increasing from a loss of CHF (622,000).
- Net Loss from Continuing Operations: CHF (1,577,000), reflecting a marginal rise from CHF (1,528,000) in Q3 2024.
Financial Overview for the Year-to-Date 2025
The year-to-date financial overview presents a narrative of cautious progress:
- Income: Total income for the year reached CHF 157,000, down significantly from CHF 408,000 in the previous year.
- Net Loss from Discontinued Operations: A stark contrast with CHF (118,000) this year against a loss of CHF (11,981,000) previously.
- Cash Position: Cash and equivalents reported as CHF 2.2 million, a decline from CHF 3.3 million a year ago.
The financial shifts largely stem from the cessation of an R&D collaboration phase. Income has primarily been influenced by costs associated with licensed patents rather than new revenue streams. This reflects the strategic pivot towards consolidating expertise in allosteric modulation.
Looking Forward
Addex Therapeutics is optimistic about its future endeavors, especially concerning its lead candidate, dipraglurant. With its focus on revitalizing stroke recovery therapies, Addex aims to leverage experimental findings to foster significant market engagement.
As Addex Therapeutics anticipates further advancements, the company remains dedicated to empowering patients combating neurological disorders through innovative therapeutics. The expectation is that their recent achievements not only position them strategically but also create new opportunities in the treatment landscape.
Frequently Asked Questions
What is Addex Therapeutics' primary focus?
Addex Therapeutics focuses on developing allosteric modulators aimed at neurological disorders.
What are the key financial highlights from Q3 2025?
Q3 2025 reported a total income of CHF 50,000 and an operating loss of CHF (696,000).
How is Addex managing its research and development expenses?
R&D expenses have seen slight increases, largely due to outsourcing costs for clinical candidates.
What challenges did Addex face in its financial performance?
Challenges include decreased income from the completion of R&D collaboration phases, leading to a tighter financial landscape.
Why should investors consider Addex stock?
Addex stock offers potential as the company continues to innovate in recovery solutions for neurological conditions.
